Managing Severe Asthma: A Role for the Long-Acting Muscarinic Antagonist Tiotropium
| العنوان: | Managing Severe Asthma: A Role for the Long-Acting Muscarinic Antagonist Tiotropium |
|---|---|
| المؤلفون: | Hamelmann, Eckard |
| المصدر: | BioMed Research International, Vol 2018 (2018) BioMed Research International |
| بيانات النشر: | Hindawi Limited, 2018. |
| سنة النشر: | 2018 |
| مصطلحات موضوعية: | medicine.medical_specialty, Severe asthma, lcsh:Medicine, Phases of clinical research, Review Article, Muscarinic Antagonists, macromolecular substances, General Biochemistry, Genetics and Molecular Biology, 03 medical and health sciences, 0302 clinical medicine, Pharmacotherapy, Adrenal Cortex Hormones, immune system diseases, Administration, Inhalation, Humans, Medicine, 030212 general & internal medicine, Tiotropium Bromide, Intensive care medicine, Asthma, General Immunology and Microbiology, Inhalation, business.industry, lcsh:R, Muscarinic antagonist, General Medicine, medicine.disease, respiratory tract diseases, Clinical trial, Clinical Trials, Phase III as Topic, 030228 respiratory system, Drug Therapy, Combination, Personalized medicine, business, medicine.drug |
| الوصف: | Severe asthma is associated with substantial morbidity and mortality. Therapies must be maximized to gain control of a patient’s severe asthma; however, avoiding overtreatment is also important. The mainstays of asthma maintenance treatment are inhaled corticosteroids (ICS) and long-acting β2-agonsits (LABAs), with the option of supplementary add-on treatments. New add-on treatments for severe asthma have emerged over the past two decades, including personalized biological therapies that are guided by a patient’s asthma phenotype. In addition, the long-acting muscarinic antagonist tiotropium has been recommended as an add-on treatment for severe asthma. Phase III clinical trials have shown tiotropium in combination with ICS/LABA to be efficacious in patients with severe asthma. Further analyses of clinical trial data have indicated that there is no benefit in stratifying patients by phenotype to predict tiotropium efficacy. Furthermore, health economic studies suggest tiotropium to be a cost-effective treatment in patients with severe asthma. This review will present the evidence surrounding the role of tiotropium in severe asthma and will discuss the use of tiotropium add-on therapy before personalized medicine strategies in the stepwise process of gaining asthma control. |
| تدمد: | 2314-6141 2314-6133 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::822b276ba0539714ac5319752836bf74Test https://doi.org/10.1155/2018/7473690Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....822b276ba0539714ac5319752836bf74 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 23146141 23146133 |
|---|